GENE ONLINE|News &
Opinion
Blog

2022-06-14| In-DepthSpecial

Ushering In A New Generation Of AI-Focused Investments Opportunities

by Reed Slater
Share To

Artificial intelligence (AI) has officially enamored the world with its plethora of potential applications. Optimistic folks see AI as a tool with the power to aid humanity and the technological revolution we live in. AI in the biotech sphere centers around drug discovery and drug repurposing. With a record number of AI-focused biotech companies forming, it is time to consider the applications, limitations, and the prospective future that investors face when confronted with AI startups looking for funding.

At the Digital Redefining Early Stage Investments (RESI) 2022 conference, Bill Kuziel, Ph.D. of MedPro Investors, sits down with three venture capital professionals to discuss the use of AI in biotechnology and its future during uncertain economic times. 

 

 

It's free! Log in now to read

LATEST
Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
2023-12-06
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
2023-12-05
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
2023-12-05
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
Unveiling the Role of Microbes in Climate Change at COP28
2023-12-04
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
EVENT
Scroll to Top